Neoadjuvant Treatment of HER2-positive Breast Cancer: Should Therapy Differ Based on Hormone Receptor Status?
Therapeutic Advances in Medical Oncology - United States
doi 10.1177/1758835918782356
Full Text
Open PDFAbstract
Available in full text
Categories
Date
January 1, 2018
Authors
Publisher
SAGE Publications